Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MIGUEL JOSE TEPEDINO

Allopathic & Osteopathic Physicians Family Medicine

NPI
1568544054
CMS profile
252933
Location
LAKE CITY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,233.98

132 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,933.98 131
Consulting Fee $300.00 1

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 132 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MIGUEL JOSE TEPEDINO

NPI 1568544054 · CMS profile ID 252933

Allopathic & Osteopathic Physicians / Family Medicine

LAKE CITY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 132 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1568544054?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MIGUEL JOSE TEPEDINO, NPI 1568544054, CMS profile ID 252933. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 132 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1568544054?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MIGUEL JOSE TEPEDINO, NPI 1568544054, CMS profile ID 252933. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 132 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1568544054?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MIGUEL JOSE TEPEDINO, NPI 1568544054, CMS profile ID 252933, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 132 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1568544054?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

132 matching records · $2,233.98 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 132 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 132.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $14.6408/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818606311 CMS
Novo Nordisk Inc $6.6708/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811219403 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $20.5808/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850358421 CMS
Novo Nordisk Inc $6.7507/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811219397 CMS
Lilly USA, LLC $13.7407/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818659391 CMS
AbbVie Inc. $5.6507/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796144609 CMS
SANOFI-AVENTIS U.S. LLC $13.9807/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843629439 CMS
Lilly USA, LLC $7.2407/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818651975 CMS
AbbVie Inc. $8.0307/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796144605 CMS
AbbVie Inc. $16.0907/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796144607 CMS
AbbVie Inc. $17.2507/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796144603 CMS
Biogen, Inc. $18.1906/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827780305 CMS
Lilly USA, LLC $5.5806/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818591271 CMS
Novo Nordisk Inc $14.5306/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811028535 CMS
Lilly USA, LLC $15.3106/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818651973 CMS
Amgen Inc. $14.8806/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825630099 CMS
Novo Nordisk Inc $5.5906/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810835565 CMS
AbbVie Inc. $3.3306/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796144601 CMS
Novo Nordisk Inc $18.2806/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810835559 CMS
Lilly USA, LLC $14.9806/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818651971 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $19.2406/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763664742 CMS
Novo Nordisk Inc $11.9705/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810835555 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.4205/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763664744 CMS
AstraZeneca Pharmaceuticals LP $14.8705/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829395269 CMS
Lilly USA, LLC $5.6605/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818665309 CMS
Novo Nordisk Inc $18.3805/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811510727 CMS
SANOFI-AVENTIS U.S. LLC $23.3405/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843629395 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $23.6605/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851913729 CMS
Lilly USA, LLC $17.2205/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818665303 CMS
Lilly USA, LLC $20.2405/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818659399 CMS
AbbVie Inc. $25.4005/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796144599 CMS
Lilly USA, LLC $13.8905/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818591269 CMS
AbbVie Inc. $4.5305/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796144597 CMS
Novo Nordisk Inc $19.8704/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811364585 CMS
AbbVie Inc. $5.3304/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796144595 CMS
Esperion Therapeutics, Inc. $21.7204/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838420451 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.5704/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763664746 CMS
Novo Nordisk Inc $16.0004/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810835549 CMS
Novo Nordisk Inc $17.5304/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810690163 CMS
AbbVie Inc. $4.7404/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796144593 CMS
Merck Sharp & Dohme Corporation $18.5704/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848586519 CMS
AbbVie Inc. $13.7004/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796144591 CMS
Lilly USA, LLC $13.9604/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818659395 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $14.6004/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851913731 CMS
AbbVie Inc. $10.4204/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796144589 CMS
AbbVie Inc. $4.8404/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796144587 CMS
Lilly USA, LLC $17.9304/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818671359 CMS
Novo Nordisk Inc $13.0003/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811510723 CMS
AbbVie Inc. $4.6703/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796144585 CMS
Novo Nordisk Inc $18.9103/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810835545 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,402.30 114
PY2020 $2,084.02 153
PY2021 $2,233.98 132
PY2022 $1,976.18 135
PY2023 $5,364.07 158
PY2024 $2,584.49 164
PY2025 $2,467.15 130

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $151,578.95 38
PY2024 Principal investigator $314,223.54 66
PY2023 Recipient $2,591.75 2
PY2023 Principal investigator $109,352.67 29
PY2022 Recipient $4,146.22 2
PY2022 Principal investigator $182,629.66 12
PY2021 Recipient $18,788.82 13
PY2021 Principal investigator $97,643.89 17
PY2020 Recipient $26,865.88 40
PY2020 Principal investigator $25,718.33 11
PY2019 Principal investigator $21,631.85 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

38 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $6,170.00 12/29/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms No dispute reported 06/30/2026 1175414821
Principal investigator 1 Astellas Pharma Global Development $978.00 11/20/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234183489
Principal investigator 1 Janssen Research & Development, LLC $412.00 11/18/2025 Non-covered Recipient Entity
Wr-Msra Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175192675
Principal investigator 1 Novartis Pharmaceuticals Corporation $91,750.95 10/27/2025 Non-covered Recipient Entity
MULTISPECIALTY RESEARCH ASS OF NC
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190306281
Principal investigator 1 Astellas Pharma Global Development $1,956.00 10/23/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234183483
Principal investigator 1 Astellas Pharma Global Development $978.00 10/16/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234183485
Principal investigator 1 Astellas Pharma Global Development $978.00 10/09/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234183487
Principal investigator 1 Janssen Research & Development, LLC $3,500.00 09/25/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175414816
Principal investigator 1 Astellas Pharma Global Development $978.00 09/23/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234183481
Principal investigator 1 Janssen Research & Development, LLC $206.00 09/05/2025 Non-covered Recipient Entity
Wr-Msra Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175192659
Principal investigator 1 Janssen Research & Development, LLC $5,400.00 08/21/2025 Non-covered Recipient Entity
Wr-Msra Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175192629
Principal investigator 1 Janssen Research & Development, LLC $870.00 08/21/2025 Non-covered Recipient Entity
Wr-Msra Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175192635
Principal investigator 1 Astellas Pharma Global Development $2,423.00 07/31/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234183479
Principal investigator 1 Janssen Research & Development, LLC $4,350.00 07/28/2025 Non-covered Recipient Entity
Wr-Msra Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175192620
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 07/14/2025 Non-covered Recipient Entity
Wr-Msra Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175192667
Principal investigator 1 Astellas Pharma Global Development $467.00 06/24/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234183477
Principal investigator 1 Astellas Pharma Global Development $978.00 06/19/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234183475
Principal investigator 1 Mylan Inc. $400.00 06/18/2025 Non-covered Recipient Entity
WRMSRALLC
MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 1238886051
Principal investigator 1 Astellas Pharma Global Development $978.00 05/28/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234183469
Principal investigator 1 Janssen Research & Development, LLC $200.00 05/19/2025 Non-covered Recipient Entity
Wr-Msra Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175192652
Principal investigator 1 Astellas Pharma Global Development $575.00 05/15/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234183471
Principal investigator 1 Astellas Pharma Global Development $978.00 05/08/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234183473
Principal investigator 1 Astellas Pharma Global Development $467.00 04/28/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234183463
Principal investigator 1 Astellas Pharma Global Development $917.00 04/08/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234183467
Principal investigator 1 Astellas Pharma Global Development $575.00 04/01/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234183465
Principal investigator 1 Astellas Pharma Global Development $467.00 03/25/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234183457
Principal investigator 1 Janssen Research & Development, LLC $780.00 03/25/2025 Non-covered Recipient Entity
Wr-Msra Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175192644
Principal investigator 1 Astellas Pharma Global Development $467.00 03/19/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234183461
Principal investigator 1 Astellas Pharma Global Development $1,834.00 03/04/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234183459
Principal investigator 1 Astellas Pharma Global Development $530.00 02/11/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234183453
Principal investigator 1 Astellas Pharma Global Development $1,025.00 02/05/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234183455
Principal investigator 1 Astellas Pharma Global Development $2,590.00 01/29/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234183443
Principal investigator 1 Astellas Pharma Global Development $3,777.00 01/21/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234183439
Principal investigator 1 Astellas Pharma Global Development $917.00 01/17/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234183441
Principal investigator 1 Astellas Pharma Global Development $1,565.00 01/07/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234183445
Principal investigator 1 Astellas Pharma Global Development $575.00 01/07/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234183447
Principal investigator 1 Astellas Pharma Global Development $2,255.00 01/07/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234183449
Principal investigator 1 Astellas Pharma Global Development $6,312.00 01/07/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1234183451